Aandeel Galapagos AEX:GLPG.NL, BE0003818359

quote:

Wall Street Trader schreef op 10 oktober 2019 19:53:

Danny Reweghs
Directeur strategie Inside Beleggen

Conclusie

We namen Galapagos deze zomer op in onze lijst van veertien Belgische langetermijnfavorieten, omdat we geloven dat het risicoprofiel voldoende is afgebouwd en het bedrijf enorm zal groeien het komende decennium. We grijpen de terugval van het aandeel aan om onze positie in de voorbeeldportefeuille te vervolledigen met een opportunistische aankooplimiet.

Advies: koopwaardig

insidebeleggen.knack.be/beurs/advieze...

quote:

abelheira schreef op 12 oktober 2019 14:17:

[...]
Ik ken Danny Reweghs nog van toen hij schreef voor Trends : een man met kennis van zaken die risicovol beleggen mijdt. Zijn woorden : GLPG zal enorm groeien het komende decennium, geeft mij het volste vertrouwen dat we nog mooie tijden tegemoet gaan met Galapagos.
Dat de beurskoers op dit ogenblik nog niet hoger staat is mij ook een raadsel.
Volgend jaar deze tijd is de kans groot dat de koers het tweevoud bedraagt van vandaag.

quote:

kampie schreef op 12 oktober 2019 16:30:

[...]

De koers een tweevoud van nu? Dat is best mogelijk. Maar dan moeten de shortinstellingen er uit zijn, want die hebben er geen enkel belang bij dat de koers over de kop gaat.

quote:

kampie schreef op 12 oktober 2019 16:30:

[...]

De koers een tweevoud van nu? Dat is best mogelijk. Maar dan moeten de shortinstellingen er uit zijn, want die hebben er geen enkel belang bij dat de koers over de kop gaat.

quote:

kampie schreef op 12 oktober 2019 16:30:

[...]

De koers een tweevoud van nu? Dat is best mogelijk. Maar dan moeten de shortinstellingen er uit zijn, want die hebben er geen enkel belang bij dat de koers over de kop gaat.

quote:

winx09 schreef op 18 oktober 2019 14:38:

uit de CHMP opinie:

"Upadacitinib preferentially inhibits signalling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2."

“Rinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Rinvoq may be used as monotherapy or in combination with methotrexate.”

quote:

pe26 schreef op 18 oktober 2019 14:05:

Geen JAK1 claim meer van AbbVie..?

AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ™) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis

- In Phase 3 trials, upadacitinib improved signs and symptoms of rheumatoid arthritis, inhibited radiographic progression and improved physical function, both as a monotherapy and in combination with conventional synthetic DMARDs[1-5]
- Upadacitinib (under the trade name RINVOQ™) is a selective and reversible JAK inhibitor discovered and developed by AbbVie[6]
PR Newswire
NORTH CHICAGO, Ill., Oct. 18, 2019 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for RINVOQ™ (upadacitinib), a once-daily selective and reversible JAK inhibitor, for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). The positive opinion is for use of upadacitinib as monotherapy or in combination with methotrexate.

The CHMP positive opinion is supported by data from the global Phase 3 SELECT rheumatoid arthritis program, evaluating more than 4,400 patients with moderate to severe active rheumatoid arthritis in five pivotal studies.1-5 Across all five trials – SELECT-NEXT, SELECT-BEYOND, SELECT-MONOTHERAPY, SELECT-COMPARE and SELECT-EARLY – all primary and ranked secondary endpoints were met, including low disease activity based on Disease Activity Score 28 C-Reactive Protein (DAS28-CRP)=3.2, clinical remission based on DAS28-CRP<2.6 and ACR20/50 (depending on study design); improved response was seen with upadacitinib both as monotherapy and in combination with conventional synthetic DMARDs compared to placebo, methotrexate or adalimumab (depending on study design).1-5 Data from the SELECT program showed a consistent safety profile across the five studies.1-5,7 The most frequently reported adverse reactions were infections.1-5

"Rheumatoid arthritis is a chronic and debilitating disease affecting an estimated 23.7 million people worldwide. While significant treatment advances have been made over the past 20 years, many people living with the disease still do not achieve remission. The need for novel, innovative treatment options is critical," said Michael Severino, M.D., vice chairman and president, AbbVie. "We are pleased with this positive opinion from the CHMP recognizing upadacitinib's potential for patients with moderate to severe active rheumatoid arthritis. This regulatory milestone marks an important step towards our pursuit of delivering innovative therapies that address the unmet needs of patients living with rheumatoid arthritis."

The CHMP positive opinion is a scientific recommendation for marketing authorization to the European Commission, which authorizes marketing approval in the European Union. The Marketing Authorization will be valid in all member states of the European Union, as well as Iceland, Liechtenstein and Norway. The Commission decision is anticipated within 67 days following the CHMP opinion.

seekingalpha.com/pr/17667160-abbvie-r...